All Stories

  1. Sestrin 2 levels are associated with emphysematous phenotype of COPD
  2. Evaluation of asthma control and quality of life after 6 months of treatment with FDC Budesonide/Formoterol-BOREAS study
  3. Inflammatory profile in optimally treated patients with adult versus early-onset asthma
  4. Experimental and investigational phosphodiesterase inhibitors in development for asthma
  5. Clinical, functional and inflammatory characteristics in patients with paucigranulocytic stable asthma: Comparison with different sputum phenotypes
  6. Sputum interleukin-13 as a biomarker for the evaluation of asthma control
  7. Vascular Biomarkers in Asthma and COPD
  8. Sputum and BAL Clara cell secretory protein and surfactant protein D levels in asthma
  9. Biomarkers in Chronic Obstructive Pulmonary Disease (COPD): Current Concerns and Future Prospects
  10. Increased Levels of Osteopontin in Sputum Supernatant in Patients With COPD
  11. The Relationship Between the Adherence to Treatment and the Psychological Profile of Patients With Chronic Obstructive Pulmonary Disease
  12. Biomarkers in Chronic Obstructive Pulmonary Disease (COPD): Current Concerns and Future Prospects
  13. Serum Angiopoietin-2 and CRP Levels During COPD Exacerbations
  14. Biomarkers in COPD: Is Mortality the Holy Grail?
  15. Vascular endothelial growth factor and cysteinyl leukotrienes in sputum supernatant of patients with asthma
  16. Noninvasive evaluation of airway inflammation in patients with severe asthma
  17. Depression, physical activity, energy consumption, and quality of life in OSA patients before and after CPAP treatment
  18. Editorial (Hot Topic: COPD Management Beyond Bronchodilation: Current Targets and Future Prospects)
  19. Increased levels of osteopontin in sputum supernatant of smoking asthmatics
  20. Systemic Biomarkers in the Evaluation and Management of COPD Patients: Are We Getting Closer to Clinical Application?
  21. Levels of angiopoietins 1 and 2 in induced sputum supernatant in patients with COPD
  22. Increased levels of angiopoietins 1 and 2 in sputum supernatant in severe refractory asthma
  23. The Inflammatory Effector Cell Pattern in Asthma and Chronic Obstructive Pulmonary Disease – What Is It Good for?
  24. Associations between BODE Index and Systemic Inflammatory Biomarkers in COPD
  25. VEGF and IL-18 in induced sputum of lung cancer patients
  26. Editorial [Hot Topic: Non-Invasive Assessment of Asthmatic Inflammation: From Bench to Bedside (Guest Editors: S. Loukides, K. Kostikas and P. Bakakos)]
  27. Induced Sputum in Asthma: From Bench to Bedside
  28. Oxidative Stress in Patients with COPD
  29. Hemoglobin, erythropoietin and systemic inflammation in exacerbations of chronic obstructive pulmonary disease
  30. The disparity of health facilities in an urban area discourages proposed treatment application in inoperable lung cancer patients
  31. The disparity of health facilities in an urban area discourages proposed treatment application in inoperable lung cancer patients
  32. Exhaled breath condensate: hydrogen peroxide
  33. Increased levels of osteopontin in sputum supernatant in severe refractory asthma
  34. Exhaled Nitric Oxide and Exhaled Breath Condensate pH in Severe Refractory Asthma
  35. COMPLIANCE OF PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE TO A PULMONARY REHABILITATION PROGRAM: ITS IMPACT ON THE OUTCOMES AND ITS PROGNOSTICATION
  36. C-reactive protein and procalcitonin as predictors of survival and septic shock in ventilator-associated pneumonia
  37. Biomarkers Obtained by Non-Invasive Methods in Patients with COPD: Where do we Stand, what do we Expect?
  38. Noninvasive evaluation of airway inflammation in asthmatic patients who smoke: implications for application in clinical practice
  39. Carcinoembryonic antigen, neuron‐specific enolase and cytokeratin fragment 19 (CYFRA 21‐1) levels in induced sputum of lung cancer patients
  40. P1746 Serum procalcitonin and organ failure in critically ill patients with sepsis
  41. P1747 The impact of insulin therapy on infiammatory markers in critically ill patients with sepsis
  42. Tuberculous Effusion: ADA Activity Correlates with CD4+ Cell Numbers in the Fluid and the Pleura
  43. Chylothorax and Pseudochylothorax
  44. TCR usage and cytokine expression in peripheral blood and BAL T cells
  45. Plasma and Urine Elastase Alpha-1-Proteinase Inhibitor Levels in Neonatal Urinary Tract Infection
  46. Regulation of allergy and asthma by T-cell Vbeta family subsets
  47. Intracellular Cytokine Staining for Analysis by Flow Cytometry